A lthough the only FDA-approved medical therapy for acute stroke to date remains intravenous tissue plasminogen activator administered within 3 hours of onset, there is increasing evidence that identification of potentially salvageable brain using advanced imaging may facilitate the selection of patients for safe and effective intravenous thrombolysis up to 9 hours postictus. [1] [2] [3] [4] [5] Specifically, the mismatch between infarct core (brain likely to be irreversibly infarcted despite treatment) and ischemic penumbra (hypoperfused brain at risk for infarction in the absence of reperfusion) may identify patients with both a low hemorrhagic risk (small core) and a high likelihood of treatment benefit (large penumbra). In clinical practice, core can be operationally defined using either MR diffusion-weighted imaging (DWI) or CT cerebral blood volume imaging, and penumbra with either MR or CT perfusion-weighted imaging (PWI); conventional unenhanced CT provides a less sensitive measure of core. 6 -8 Because many sites do not currently have access to advanced CT and MR modalities, however, and not all patients are candidates for such scanning even when it is available, there has been interest in using the mismatch between CT hypodensity and clinical NIHSS as a surrogate for radiographic core/penumbra mismatch.
In this issue of Stroke, Messe et al 9 report that, for a community-based cohort of acute stroke patients, CT/NIHSS mismatch "could not be validated as a means to identify ischemic penumbra as defined by MRI diffusion-perfusion mismatch." MRI mismatch (Ͼ25%) was present in 41% of 143 patients scanned 2.5 to 13.9 hours after stroke onset (median, 4.5 hours). Despite an association between mismatch and higher NIHSS scores in univariate analysis, only shorter time-to-scan was associated with MRI mismatch in multivariate analysis ( 10 These results expand on those of an earlier study by Kent et al, 11 which concluded, using a combined database of 2131 patients from 4 major clinical trials of IV thrombolytic therapy, that "clinical-CT mismatch . . . does not reliably identify patients more or less likely to benefit from IV tPA."
Given these findings, does there remain a potential role for imaging/clinical mismatch when perfusion scanning is neither available nor advisable? For certain highly selected patients with focal clinical syndromes, and for whom DWI, which is more sensitive than CT for overall stroke detection 12 can be obtained, the answer may be a qualified "yes." In a study of 81 consecutive patients with acute-onset aphasia, simple brief tests of oral naming or repetition were successfully used to estimate the PWI lesion and produce a clinical diffusion mismatch score that correlated with short-term language improvement (PϽ0.02). 13 This suggests that a more sophisticated "location-weighted" scoring system for rating ischemic lesions, one that assigns higher values to critical regions, including language and primary motor areas, might more closely correlate with clinical NIHSS score than a simple volume-weighted system, such as the Alberta Stroke Program Early CT Score (ASPECTS). In a series of 80 patients rated using such an atlas-based approach, volumebased estimates of stroke severity were only moderately correlated with NIHSS (rϭ0.62), whereas combined volume/location based estimates were significantly better correlated with NIHSS (rϭ0.79; Pϭ0.03). 14 In another study that used a DWI lesion volume cutoff of 25 mL and an NIHSS cutoff of 8 to define clinical diffusion mismatch, MR diffusion/perfusion mismatch was detected with high specificity (93%) and positive predictive value (95%), but low sensitivity (53%). 15 Subacute infarct growth was higher in those with clinical diffusion mismatch than without (Pϭ0.01). A more recent study had similar success in predicting the risk of early neurological decline (PϽ0.05). 16 Moreover, an abstract presented at this year's International Stroke Conference has proposed that "adjusting the definition of clinical-diffusion mismatch to patient deficit severity, rather than applying a fixed threshold to all patients, improves sensitivity and overall accuracy in identifying patients harboring treatable penumbral tissue." 17 In this investigation, using a severity adjusted definition of clinical diffusion mismatch identified Ͼ90% of all stroke patients with salvageable penumbra.
The studies cited above all measured DWI/NIHSS mismatch. Might similar results be possible for some patients using CT/ NIHSS mismatch? It has been estimated that up to 20% of acute stroke patients are unable to undergo MRI for various reasons. 18 Unfortunately, although certain subgroups in both the Messe and Kent articles displayed a weak trend toward a correlation between CT/NIHSS mismatch and either MRI mismatch (Pϭ0.11 in the third row of Table 2 ) 9 or intravenous tissue plasminogen activator benefit (Pϭ0.08 in the third row of Table  2 ), 11 attempts to increase specificity by such stratification introduce the possibility of spectral bias. 19 As underscored by Messe et al, because their cases consisted mostly of mild strokes (median admission NIHSS 4), a larger cohort of exclusively severe strokes may be required to reveal an association between CT/NIHSS and DWI/PWI mismatch.
The conclusions of Messe et al are not only in agreement with those of recent post hoc analyses of major thrombolytic trials performed within the 3-hour window (including the NINDS rt-PA study) but also, more importantly, are applicable to patients who presented well beyond 6 hours (25% presented after 14 hours). This is noteworthy because, despite the fact that the sensitivity of unenhanced CT for stroke detection more closely approximates that of DWI at these later time points, still no correlation between CT/NIHSS and DWI/PWI mismatch was observed.
In summary, CT/NIHSS mismatch, compared with MRI mismatch, does indeed appear to be overrated for the detection of salvageable penumbra when selecting thrombolysis candidates beyond a 3-hour window. When PWI is not available or contraindicated, but DWI can be performed, DWI/NIHSS mismatch may be of value for certain patients. Although many investigators have both advocated CT perfusion imaging as a reliable method for detecting infarct core, and established thresholds for delineating salvageable penumbra, 14 -16 almost all of the major clinical trials aimed at extending the time window for thrombolysis have used advanced MR rather than CT imaging for triage. Because CT scanning is typically faster and more available than is MRI, as these major trials continue to evolve into a new standard of care, further validation and standardization is urgently required to determine the degree to which CT perfusion measures of mismatch are interchangeable with their MR DWI/PWI counterparts. 20 
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